Prescribing patterns of antiretroviral treatments during pregnancy for women living with HIV in Canada 2004–2020: A surveillance study. Issue 2 (14th June 2022)

• Record Type: Journal Article
• Authors: Carvalho, Sabrina; Lee, Terry; Tulloch, Karen J; Sauve, Laura J; Samson, Lindy; Brophy, Jason C; Bitnun, Ari; Singer, Joel; Money, Deborah; Kakkar, Fatima; Boucoiran, Isabelle
• Is Part Of: HIV medicine. Volume 24:Issue 2(2023)
• Page Start: 130
• Page End: 138
• Publication Date: 2022-06-14
• Subjects: antiretroviral treatments -- Canada -- guidelines -- HIV -- pregnancy -- prescribing patterns; HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.13346
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract: Background: While treatment guidelines for HIV in adults have evolved rapidly with the advent of new antiretroviral (ARV) treatment, those for the prevention of vertical HIV transmission in pregnancy have evolved more slowly due to safety and efficacy concerns. Here we describe Canadian prescribing patterns for ARV treatments during pregnancy and compare them to perinatal HIV prescribing guidelines of the United States Department of Health and Human Services (HHS), that are commonly used in Canada and include recommendations for newly commercialized therapies. Methods: The Canadian Perinatal HIV Surveillance Program (CPHSP) captures annual medical data on mothers living with HIV and their infants from 23 sites across Canada. Women from this cohort who received an ARV treatment during pregnancy and who gave birth between 2004 and 2020 were included in the study. ARV treatments were designated as 'preferred/alternative' as per HHS HIV perinatal guidelines, or 'other than preferred/alternative'. Results: We identified 3673 pregnancies from 2720 women. The proportion of women that conceived while on ARV treatment increased from 29% in 2003 to 90% in 2020. Other than preferred/alternative ARV treatments were received in 1112 (30%) of pregnancies and this was significantly associated with having initiated ARV treatment before conception. Conclusion: In Canada during the study period, a high number of women were prescribed an other than preferred/alternative ARV treatment during pregnancy. Further optimization of ARV treatment in women of childbearing age living with HIV is warranted.